Revolutionize Your Health: Alphabet’s AI-Powered Medicine Breakthrough Lands $600M Investment

Alphabet’s AI Drug Discovery Platform Isomorphic Labs Raises $600M from Thrive

In a significant move, Isomorphic Labs, Alphabet’s AI-driven drug discovery platform, has secured a whopping $600 million in funding. This substantial influx of capital was led by Thrive Capital, with participation from GV and existing investor Google’s parent Alphabet.

The freshly raised funds will be used to accelerate the further development of Isomorphic Labs’ AI drug design engine and support its ambitious goal of bringing discovered drugs to clinical trials. Notably, this is the first time the platform has received external capital since its inception in 2021 as a spin-off from Google’s DeepMind.

The company was founded by none other than Demis Hassabis, co-founder of DeepMind, who leveraged DeepMind’s software for AI drug discovery, including AlphaFold, an AI model that predicts the three-dimensional structures of proteins. In an earlier development, Isomorphic Labs had secured strategic partnerships with major pharmaceutical companies Eli Lilly and Novartis last year, which could potentially generate up to $3 billion in milestone payments for access to its AI model.

In a statement, Hassabis emphasized that while Isomorphic Labs didn’t necessarily need the capital, the additional funding will enable the company to hire top research scientists. It is worth noting that Demis Hassabis and DeepMind researcher John Jumper received the Nobel Prize in Chemistry in 2024 for their work on AlphaFold.

Isomorphic Labs’ recent achievement highlights its commitment to revolutionizing the drug discovery process through the strategic integration of AI technology.

Source: https://techcrunch.com/2025/03/31/alphabets-ai-drug-discovery-platform-isomorphic-labs-raises-600m-from-thrive/